Results 61 to 70 of about 204,961 (215)
Atorvastatin’s Therapeutic Potential in Atherosclerosis: Inhibiting TGF-β-Induced Proteoglycan Glycosaminoglycan Chain Elongation through ROS-ERK1/2-Smad2L Signaling Pathway Modulation in Vascular Smooth Muscle Cells [PDF]
Cell JournalObjective: According to the response-to-retention hypothesis, the inception of atherosclerosis is attributed to thedeposition and retention of lipoprotein in the arterial intima, facilitated by altered proteoglycans with hyperelongatedglycosaminoglycan ...
Hossein Ghaderi-Zefrehi +4 more
doaj +1 more source
The loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.
American Journal of Physiology. Regulatory Integrative and Comparative Physiology, 2019 Agonists for PPARα are used clinically to reduce triglycerides and improve high-density lipoprotein (HDL) cholesterol levels in patients with hyperlipidemia.
D. Stec +9 more
semanticscholar +1 more source
Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis.
Journal of Lipid Research, 1992 The relationship between apoE phenotype and plasma lipid levels was analyzed in the combined data of published studies. Accordingly, 45 population samples from 17 different countries were included in the analysis.
J Dallongeville +2 more
doaj
PLoS ONE, 2020 BackgroundPsoriasis is associated with hyperlipidemia. Few studies have examined the association among psoriasis, hyperlipidemia, and chronic kidney disease (CKD).
Kwei-Lan Liu +3 more
doaj +1 more source
Oncogene, 2017 Obesity is associated with an increase in cancer-specific mortality in women with breast cancer. Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in obese women. Here, we aimed to determine the importance
E. Gallagher +6 more
semanticscholar +1 more source
Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects
Journal of Lipid Research, 2002 ApoC-I has several different lipid-regulating functions including, inhibition of receptor-mediated uptake of plasma triglyceride-rich lipoproteins, inhibition of cholesteryl ester transfer activity, and mediation of tissue fatty acid uptake. Since little
Jeffrey S. Cohn +8 more
doaj
International Journal of Molecular Sciences, 2019 Holothuria leucospilota polysaccharides (HLP) are expected to become potential resources for the treatment of hyperlipidemia because of their various bioactivities. In the study, the treatment of HLP on improving hyperlipidemia in rats was explored. Oral
Yiqiong Yuan +5 more
semanticscholar +1 more source
In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma
Journal of Lipid Research, 1998 Gamma-LpE (γ-LpE), a sphingomyelin-rich lipoprotein that contains apolipoprotein (apo) E as its only protein component, has been proposed to play a role in cellular cholesterol efflux by acting, like pre-β1-LpA-I, as an initial acceptor of cell-derived ...
Larbi Krimbou +4 more
doaj
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
New England Journal of Medicine, 2014 BACKGROUND Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies.
D. Blom +15 more
semanticscholar +1 more source
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans
Journal of Lipid Research, 2003 Numerous factors are known to affect the plasma metabolism of HDL, including lipoprotein receptors, lipid transfer protein, lipolytic enzymes and HDL apolipoproteins.
Jeffrey S. Cohn +7 more
doaj